Clinical trial
A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
NCT01189266 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 9, 2010
- Completion date
- September 30, 2021
- Enrollment
- 79 (actual)
- Sites
- 180
Conditions
As the registry lists them; a condition with its own page is linked.
anaplastic astrocytoma, anaplastic oligoastrocytoma, diffuse intrinsic pontine glioma, gliosarcoma